PE SAN 1'0/800,840 PATENT

FEB 0 6 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket:

Gordon J. Dow et al. Examiner:

San Ming R Hui

erial No.: 10/800,840 Group Art Unit: 1617

Filed: March 15, 2004

2102.010US2

Title: FLUTICASONE LOTION HAVING IMPROVED VASOCONSTRICTOR

ACTIVITY

INFORMATION DISCLOSURE STATEMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants hereby authorize the Commissoner to charge the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p), to Deposit Account No. 19-0743. Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

Pursuant to 37 C.F.R. §1.98(d), copies of the listed documents are not provided as these references were previously cited by or submitted to the U.S. Patent Office in connection with Applicants' prior U.S. application, Serial No. <u>09830037</u>, filed on <u>April 20, 2001</u>, which is relied upon for an earlier filing date under 35 U.S.C. §120.

Filing Date: March 15, 2004

Title: FLUTICASONE LOTION HAVING IMPROVED VASOCONSTRICTOR ACTIVITY

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications, and Non-Published Applications identifiable by USPTO Serial Number, are no longer required to be provided to the Office. Notification of this change to this effect was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004 and October 19, 2004. Thus, Applicant has not included copies of any US Patents or US Patent Applications identifiable by serial number that may be cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

GORDON J. DOW ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938 Minneapolis, MN 55402 (612) 373-6941

Date + 4 1,2007

Reg. No. 51,266

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexendria, VA 22313-1450 on this 1ST day of February 2007.

Patricia A. Hultman

Name

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
on of information unless it contains a waif OMB control number.

Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/800,840	
(Use as many, sheets as necessary)	Filing Date	March 15, 2004	
O AND THE REST OF THE PARTY OF	First Named Inventor	Dow, Gordon	
FEB 0 6 2007 W	Group Art Unit	1617	
\	Examiner Name	Hui, San Ming	
STEADED 1	Attorney Docket No: 2102.010US2		

US PATENT DOCUMENTS							
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate			
	US-4,985,418	01/15/1991	Richards, David A.	12/23/1987			

	FOR	REIGN PATENT I	DOCUMENTS	
Examiner Foreign Document No		Publication Date	Name of Patentee or Applicant of cited Document	T²
	EP-0042827	12/30/1981	Bergstrom, Karl O., et al.	
	WO-9214472	09/03/1992	Hill, Ernest A.	

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		"Physicians' Desk Reference monographs", 7 pages	
		"Potency Ranking of Some Commonly Used Topical Corticosteroids",	
		Temovate literature, 1 page	
		BLEEHEN, S S., et al., "Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment.", <u>British Journal of Dermatology</u> , 133(4), (1995),592-597	
		BUDAVARI, SUSAN, et al., "Monographs 6021 and 7879", Merck Index 11th ed., Rahway, N.J.: Merck,(1989),	
13.00		CORNELL, ROGER C., et al., "Potency Ranking of Some Commonly Used Topical Steroids", <u>Topical Corticosteroids - Guidelines for Therapy Hoechst-Roussel Pharmaceuticals Inc.</u> , (1985),24-25	
		GORDON, M. L., "The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses.", Clinical Therapeutics, 20(1), (Feb., 1998),26-39	
		SPENCER, CAROLINE M., "Topical Fluticasone Propionate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders", Biodrugs, 7(4), (1997),318-334	

EXAMINER DATE CONSIDERED